Catherine Bresson
Overview
Explore the profile of Catherine Bresson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
284
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
El-Deiry W, Bresson C, Wunder F, Carneiro B, Dizon D, Warner J, et al.
Oncotarget
. 2025 Mar;
16:140-162.
PMID: 40073368
The human genome project ushered in a genomic medicine era that was largely unimaginable three decades ago. Discoveries of druggable cancer drivers enabled biomarker-driven gene- and immune-targeted therapy and transformed...
2.
Lazar V, Raymond E, Magidi S, Bresson C, Wunder F, Berindan-Neagoe I, et al.
Ther Adv Med Oncol
. 2024 Oct;
16:17588359241289200.
PMID: 39429467
Background: Dysregulated pathways in cancer may be hub addicted. Identifying these dysregulated networks for targeting might lead to novel therapeutic options. Objective: Considering the hypothesis that central hubs are associated...
3.
Lazar V, Zhang B, Magidi S, Le Tourneau C, Raymond E, Ducreux M, et al.
Ther Adv Med Oncol
. 2023 Apr;
15:17588359231156382.
PMID: 37025260
Background: The current model of clinical drug development in oncology displays major limitations due to a high attrition rate in patient enrollment in early phase trials and a high failure...
4.
Lazar V, Raynaud J, Magidi S, Bresson C, Martini J, Galbraith S, et al.
Ther Adv Med Oncol
. 2022 Nov;
14:17588359221133893.
PMID: 36324736
Background: SARS-CoV-2 (COVID-19) elicits a T-cell antigen-mediated immune response of variable efficacy. To understand this variability, we explored transcriptomic expression of angiotensin-converting enzyme 2 (, the SARS-CoV-2 receptor) and of...
5.
Lazar V, Girard N, Raymond E, Martini J, Galbraith S, Raynaud J, et al.
JCO Precis Oncol
. 2022 Sep;
6:e2200072.
PMID: 36108261
Purpose: The prognosis of patients with non-small-cell lung cancer (NSCLC), traditionally determined by anatomic histology and TNM staging, neglects the biological features of the tumor that may be important in...
6.
Solomon B, Callejo A, Bar J, Berchem G, Bazhenova L, Saintigny P, et al.
Cancer Med
. 2022 Mar;
11(14):2790-2800.
PMID: 35307972
Background: The Worldwide Innovative Network (WIN) Consortium has developed the Simplified Interventional Mapping System (SIMS) to better define the cancer molecular milieu based on genomics/transcriptomics from tumor and analogous normal...
7.
Lazar V, Magidi S, Girard N, Savignoni A, Martini J, Massimini G, et al.
NPJ Precis Oncol
. 2021 Apr;
5(1):33.
PMID: 33911192
The expanding targeted therapy landscape requires combinatorial biomarkers for patient stratification and treatment selection. This requires simultaneous exploration of multiple genes of relevant networks to account for the complexity of...
8.
Rodon J, Soria J, Berger R, Miller W, Rubin E, Kugel A, et al.
Nat Med
. 2019 Apr;
25(5):751-758.
PMID: 31011205
Precision medicine focuses on DNA abnormalities, but not all tumors have tractable genomic alterations. The WINTHER trial ( NCT01856296 ) navigated patients to therapy on the basis of fresh biopsy-derived...
9.
Lazar V, Rubin E, Depil S, Pawitan Y, Martini J, Gomez-Navarro J, et al.
Oncotarget
. 2015 May;
6(16):14139-52.
PMID: 25944621
Non-small cell lung cancer (NSCLC) is a leading cause of death worldwide. Targeted monotherapies produce high regression rates, albeit for limited patient subgroups, who inevitably succumb. We present a novel...